Nantong University
↗Nantong, China
Nantong University (NTU) is a comprehensive public university in China with a distinguished history in medical and pharmaceutical research. Established in 1912 through the merger of several specialized schools, it has evolved into a major research hub in the Yangtze River Delta. The university is particularly recognized for its School of Medicine and School of Pharmacy, which drive significant innovation in neuroregeneration, oncology, and pharmacology. It operates several high-level research platforms, including the National-local Joint Engineering Research Center and the Key Laboratory of the Ministry of Education.
In the pharmaceutical industry context, NTU serves as a critical R&D engine and clinical trial site through its primary affiliate, the Affiliated Hospital of Nantong University. The institution is a leader in translational medicine, frequently collaborating with global pharmaceutical companies like Takeda, AbbVie, and BeiGene for Phase II and III clinical trials. Its research output is prolific, with disciplines such as Clinical Medicine, Pharmacology & Toxicology, and Neuroscience & Behavior ranking in the top 1% of the Essential Science Indicators (ESI) globally.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Academic Research & Clinical Development
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$100M-$500M
Founded:1912
Ownership:government
Status:operating
FUNDING
Investors:Jiangsu Provincial People's Government, National Department of Transportation
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Clinical Trial Site/Collaborator)
Modalities:Small molecule, Cell therapy, mAb, RNA, Regenerative Medicine
Active Trials:45
Trial Phases:Phase 1: 5 | Phase 2: 15 | Phase 3: 20 | Phase 4: 5
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Affiliated Hospital of Nantong University, Siena College of Future Biotechnology, Nantong University Technology Transfer Center
Key Partnerships:Takeda (Clinical trial site for Zasocitinib), AbbVie (Clinical trial site for Upadacitinib), BeiGene (Clinical trial site for BGB-45035), University of Siena (Biotechnology education and research), Tongji University (Lung cancer research collaboration)
COMPETITION
Position:Emerging
Competitors:Nanjing Medical University, Soochow University, Shanghai Jiao Tong University School of Medicine
LEADERSHIP
Key Executives:
Gu Xiaosong - Director, Key Laboratory of Neuroregeneration
Lin Luo - Professor, School of Pharmacy
Yuquan Zhang - Clinical Lead, Affiliated Hospital
Scientific Founders:Zhang Jian (Founder (1912))
LINKS
Website:ntu.edu.cn
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nantong University. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.